Edesa Biotech, Inc. (EDSA)

Market Cap	13.67M
Revenue (ttm)	n/a
Net Income (ttm)	-7.72M
Shares Out	3.17M
EPS (ttm)	-2.63
PE Ratio	n/a
Forward PE	0.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,021
Open	4.696
Previous Close	4.440
Day's Range	4.290 - 4.726
52-Week Range	2.460 - 8.610
Beta	0.92
Analysts	Strong Buy
Price Target	39.00 (+804.87%)
Earnings Date	May 9, 2024

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic cont...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: EDSA

Analyst Forecast

According to 2 analysts, the average rating for EDSA stock is "Strong Buy." The 12-month stock price forecast is $39.0, which is an increase of 804.87% from the latest price.

Price Target

$39.0

(804.87% upside)

Analyst Consensus: Strong Buy